Phathom Pharmaceuticals, Inc. (PHAT)

Market Cap	943.73M
Revenue (ttm)	147.19M
Net Income (ttm)	-274.55M
Shares Out	69.65M
EPS (ttm)	-3.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,433,391
Open	14.43
Previous Close	13.31
Day's Range	13.11 - 14.43
52-Week Range	2.21 - 19.50
Beta	0.44
Analysts	Strong Buy
Price Target	17.60 (+29.89%)
Earnings Date	Oct 30, 2025

About PHAT

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinoph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 427
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAT
• Website: https://www.phathompharma.com

Financial Performance

In 2024, Phathom Pharmaceuticals's revenue was $55.25 million, an increase of 8001.47% compared to the previous year's $682,000. Losses were -$334.33 million, 65.8% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price target is $17.6, which is an increase of 29.89% from the latest price.

Price Target

$17.6

(29.89% upside)

Analyst Consensus: Strong Buy